JMJD2D Antibody - BSA Free

Western Blot: JMJD2D Antibody [NBP1-03357] - Western Blot Image of anti-JMJD2D. Whole cell protein from PC3 (lane 1), SHSY5Y (lane 2), and HeLa (lane 3) was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-JMJD2D in 1% milk, and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.

• Reactivity: Hu, Pm
• Applications: WB, ChIP, ChIP, ICC/IF (-)
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1 mg/ml

JMJD2D Antibody - BSA Free Summary

• Immunogen: Synthetic peptide made to a C-terminal portion of the human JMJD2D protein (within residues 460-520). [Swiss-Prot# Q6B0I6]
• Localization: Nucleus
• Predicted Species: Primate (92%). Backed by our 100% Guarantee.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: KDM4D
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Chromatin Immunoprecipitation (ChIP)
  • Chromatin Immunoprecipitation reported in scientific literature
  • Western Blot 0.2 ug/ml
• Application Notes: This JMJD2D antibody is useful for Western blot, where a band is seen at ~55 kDa. This antibody is not useful for ICC/IF. The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Theoretical MW: 55 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Control:

  HeLa Nuclear Cell Lysate
  JMJD2D Overexpression Lysate

Reactivity Notes

Immunogen displays the following percentage of sequence identity for non-tested species: monkey (92%).

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.02% Sodium Azide
• Concentration: 1 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for JMJD2D Antibody - BSA Free

• EC 1.14.11
• EC 1.14.11.-
• FLJ10251
• JHDM3D
• JmjC domain-containing histone demethylation protein 3D
• JMJD2D
• JMJD2Dlysine-specific demethylase 4D
• jumonji domain containing 2D
• Jumonji domain-containing protein 2D
• KDM4D
• lysine (K)-specific demethylase 4D
• MGC141909

Background

Jumonji lysine demethylases (JMJDs) are oxygenases catalyzing the demethylation of mono-, di-, or trimethylated lysines, and its members (JMJD2A, JMJD2B, JMJD2C, and JMJD2D/ KDM4D) are Fe(II)-/alpha-ketoglutarate-dependent enzymes harboring a JmjC catalytic domain. JMJD2 shows differential substrate specificities and unlike, JMJD2A, JMJD2B, and JMJD2C that efficiently demethylate H3K9me3 as well as H3K36me3, JMJD2D is specific for H3K9me3 site. These enzymes have been implicated in transcriptional regulation, cell-cycle progression, nuclear hormone signaling, embryonic stem cell self-renewal and development. Overexpression of several JMJD2 homologs has been linked to cancer e.g. JMJD2D, JMJD2A and JMJD2C are overexpressed in prostate cancer wherein they function as AR coactivators to upregulate AR target genes and JMJD2D has been shown to function as a pro-proliferative protein in colon cancer cells. JMJD2D has also been reported to interact with the ligand binding domain of AR and thereby activate AR gene transcription.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for JMJD2D Antibody (NBP1-03357)(3)

Publications using NBP1-03357

• Duan L, Perez RE, Calhoun S, Maki CG Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15 Cancer biology & therapy 2022-12-31 [PMID: 35100078] (WB)
• Duan, L;Perez, RE;Chastain, PD;Mathew, MT;Bijukumar, DR;Maki, CG; JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells Oncogene 2019-04-09 [PMID: 30967636] (WB, Human)
• Luo W, Chang R, Zhong J, Pandey A, Semenza GL. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci U S A. 2012-12-04 [PMID: 23129632] (Chemotaxis, Human)

Reviews for JMJD2D Antibody (NBP1-03357) (2)

Average Rating: 5

(Based on 2 reviews)

We have 2 reviews tested in 1 species: Human.

reviewed by: ramzi abbassi WB Human 03/25/2019

Summary

• Application: Western Blot
• Sample Tested: glioblastoma cell lysates,primary cancer cells
• Species: Human
• Lot: B-2

Comments

• Comments: Bolt system (Life Technologies) was used. Prior to running the gel, DTT was added to the samples and samples were heated for 5 min at 95 degrees Celsius and rapidly cooled on ice.

reviewed by: Verified Customer WB Human 01/11/2012

Summary

• Application: Western Blot
• Sample Tested: MDA-MB-435 cell lysates
• Species: Human

Bioinformatics

• Gene Symbol: KDM4D
• Entrez:
  • 55693(Human)
• Uniprot:
  • Q6B0I6(Human)